Breast cancer (BC) is the most common malignancy diagnosed in females. Over the years, many factors have been studied to understand what causes BC to come back. One of them is the tumor size at the beginning of the treatment. Tumor size is an interesting parameter, and some classifications of cancer grade depend on it. This bibliometric analysis examined the pattern followed by publications on BC recurrence and tumor size. The Scopus database was used, and bibliometric analysis was utilized to identify the most prolific authors, the journals most involved in the field, and the countries, institutions, and keywords used. BC recurrence and tumor size have an exponential growth in the number of publications over the years. For the last 11 years, from 2012 to 2022, the trend of annual publications concerning BC recurrence and tumor size increased dramatically, showing that the majority of publications were published in the United States (452 articles) by Morrow, M., who authored 13 articles; The University of Texas, Anderson Cancer Center had the most published articles (48 articles); and Breast Cancer Research and Treatment journal achieved the largest quantity of published articles (112 articles). Tumor size is an important risk factor for BC recurrence, and this bibliometric analysis focused on the high interest introduced by the research community.
{"title":"Breast cancer recurrence and tumor size: A bibliometric analysis","authors":"Heba Ramadan","doi":"10.2478/fco-2023-0025","DOIUrl":"https://doi.org/10.2478/fco-2023-0025","url":null,"abstract":"\u0000 \u0000 \u0000 Breast cancer (BC) is the most common malignancy diagnosed in females. Over the years, many factors have been studied to understand what causes BC to come back. One of them is the tumor size at the beginning of the treatment. Tumor size is an interesting parameter, and some classifications of cancer grade depend on it.\u0000 \u0000 \u0000 \u0000 This bibliometric analysis examined the pattern followed by publications on BC recurrence and tumor size. The Scopus database was used, and bibliometric analysis was utilized to identify the most prolific authors, the journals most involved in the field, and the countries, institutions, and keywords used. BC recurrence and tumor size have an exponential growth in the number of publications over the years.\u0000 \u0000 \u0000 \u0000 For the last 11 years, from 2012 to 2022, the trend of annual publications concerning BC recurrence and tumor size increased dramatically, showing that the majority of publications were published in the United States (452 articles) by Morrow, M., who authored 13 articles; The University of Texas, Anderson Cancer Center had the most published articles (48 articles); and Breast Cancer Research and Treatment journal achieved the largest quantity of published articles (112 articles).\u0000 \u0000 \u0000 \u0000 Tumor size is an important risk factor for BC recurrence, and this bibliometric analysis focused on the high interest introduced by the research community.\u0000","PeriodicalId":38592,"journal":{"name":"Forum of Clinical Oncology","volume":" 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141824582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
D. Rothwell, J. Sousa, R. Magalhães, I. Guimarães, B. Pires, J. Barros, R. Leite, Mónica Rodrigues, Carla Alves, Cristina Miranda, Gilberto Melo, P. Alves
Abstract Background Temporary prostate brachytherapy, in combination with external beam radiotherapy (EBRT), is an established and evolving treatment technique for non-metastatic, intermediate and high-risk prostate cancer. This study aimed to evaluate the outcomes of patients with localized intermediate and high-risk prostate cancer treated with combined EBRT and high-dose-rate brachytherapy boost (HDR-BT) at a single centre. Patients & Methods A retrospective review of patients who underwent EBRT and HDR-BT treatment between January 2015 and December 2020. Patient and tumor characteristics, treatment outcomes (Kaplan-Meier analysis), and toxicities were analysed. Results 127 patients with intermediate (28.3%) or high-risk (71.7%) prostate cancer were included. Median follow-up was 42 months. Five-year bDFS, CSS and OS rate was 77.5%, 98.1% and 93.0%, respectively, with no significant difference between risk groups. The most frequent toxicity was acute grade 1 urinary obstruction (7.9%). One patient experienced acute and late grade 3 urinary obstruction. No grade ≥4 were observed. Conclusions Combined EBRT and HDR-BT demonstrated favourable disease control rates and manageable toxicities in patients with localized intermediate and high-risk prostate cancer. The 5-year bDFS rate was consistent with previous studies, supporting the effectiveness of this treatment approach. The low incidence of toxicities highlights the conformality and biological efficiency of HDR-BT boost. This treatment strategy provides an effective, safe and convenient option for this group of patients. To the best of our knowledge, this is the first report of the use of helical tomotherapy based intensity-modulated radiation therapy in combination with prostate HDR-BT (81.1% of cases).
{"title":"Outcomes of patients with localized prostate cancer treated with combined external beam radiotherapy and high-dose-rate brachytherapy boost: A single-center retrospective study","authors":"D. Rothwell, J. Sousa, R. Magalhães, I. Guimarães, B. Pires, J. Barros, R. Leite, Mónica Rodrigues, Carla Alves, Cristina Miranda, Gilberto Melo, P. Alves","doi":"10.2478/fco-2023-0020","DOIUrl":"https://doi.org/10.2478/fco-2023-0020","url":null,"abstract":"Abstract Background Temporary prostate brachytherapy, in combination with external beam radiotherapy (EBRT), is an established and evolving treatment technique for non-metastatic, intermediate and high-risk prostate cancer. This study aimed to evaluate the outcomes of patients with localized intermediate and high-risk prostate cancer treated with combined EBRT and high-dose-rate brachytherapy boost (HDR-BT) at a single centre. Patients & Methods A retrospective review of patients who underwent EBRT and HDR-BT treatment between January 2015 and December 2020. Patient and tumor characteristics, treatment outcomes (Kaplan-Meier analysis), and toxicities were analysed. Results 127 patients with intermediate (28.3%) or high-risk (71.7%) prostate cancer were included. Median follow-up was 42 months. Five-year bDFS, CSS and OS rate was 77.5%, 98.1% and 93.0%, respectively, with no significant difference between risk groups. The most frequent toxicity was acute grade 1 urinary obstruction (7.9%). One patient experienced acute and late grade 3 urinary obstruction. No grade ≥4 were observed. Conclusions Combined EBRT and HDR-BT demonstrated favourable disease control rates and manageable toxicities in patients with localized intermediate and high-risk prostate cancer. The 5-year bDFS rate was consistent with previous studies, supporting the effectiveness of this treatment approach. The low incidence of toxicities highlights the conformality and biological efficiency of HDR-BT boost. This treatment strategy provides an effective, safe and convenient option for this group of patients. To the best of our knowledge, this is the first report of the use of helical tomotherapy based intensity-modulated radiation therapy in combination with prostate HDR-BT (81.1% of cases).","PeriodicalId":38592,"journal":{"name":"Forum of Clinical Oncology","volume":" 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141372055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
We wish to investigate whether there is a known connection between prostate cancer and glomerulonephritis. We present a case report of a patient whom we diagnosed with rapidly progressive glomerulonephritis as a result of prostate cancer relapse. In rare cases, prostate cancer is associated with crescentic glomerulonephritis. Every patient with cryptic glomerulonephritis should be screened for cancer.
{"title":"Glomerulonephritis as a paraneoplastic event from prostate cancer relapse","authors":"Fotis Konstantinou, Dimitra Dimitriou, Florentia Savva, Theognosia Channi","doi":"10.2478/fco-2023-0019","DOIUrl":"https://doi.org/10.2478/fco-2023-0019","url":null,"abstract":"\u0000 \u0000 \u0000 We wish to investigate whether there is a known connection between prostate cancer and glomerulonephritis.\u0000 \u0000 \u0000 \u0000 We present a case report of a patient whom we diagnosed with rapidly progressive glomerulonephritis as a result of prostate cancer relapse.\u0000 \u0000 \u0000 \u0000 In rare cases, prostate cancer is associated with crescentic glomerulonephritis.\u0000 \u0000 \u0000 \u0000 Every patient with cryptic glomerulonephritis should be screened for cancer.\u0000","PeriodicalId":38592,"journal":{"name":"Forum of Clinical Oncology","volume":"17 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141104482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Drug dosing based on the body surface area (BSA) has been the mainstay of oncological treatment over the last decades. Although this seems to be an adequate measure of an individual’s appropriate dose for traditional chemotherapeutic drugs according to their somatometric data, it is currently being questioned due to the delivery of novel treatments such as monoclonal antibodies. Most modern regimes require either a flat (fixed)-dosing model, independent of body weight, or a weight-based administration pattern, mainly depending on specific pharmacokinetic data. However, even in this case, some controversy exists about whether this model is sufficient. Given the recent findings from pharmacokinetic studies, perhaps we should reconsider the solid hypothesis that drug efficacy correlates with dose, as many molecules seem to be efficient even in the lowest doses administered, with minimum toxicity.
{"title":"Change of dosing paradigm in oncology","authors":"Sophia Papakatsika, Myrsini Orfanidou, Elpiniki Rentzeperi, Christos Emmanouilides","doi":"10.2478/fco-2023-0022","DOIUrl":"https://doi.org/10.2478/fco-2023-0022","url":null,"abstract":"\u0000 Drug dosing based on the body surface area (BSA) has been the mainstay of oncological treatment over the last decades. Although this seems to be an adequate measure of an individual’s appropriate dose for traditional chemotherapeutic drugs according to their somatometric data, it is currently being questioned due to the delivery of novel treatments such as monoclonal antibodies. Most modern regimes require either a flat (fixed)-dosing model, independent of body weight, or a weight-based administration pattern, mainly depending on specific pharmacokinetic data. However, even in this case, some controversy exists about whether this model is sufficient. Given the recent findings from pharmacokinetic studies, perhaps we should reconsider the solid hypothesis that drug efficacy correlates with dose, as many molecules seem to be efficient even in the lowest doses administered, with minimum toxicity.","PeriodicalId":38592,"journal":{"name":"Forum of Clinical Oncology","volume":"21 10","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141122501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ioannis Gavalas, M. Trichas, Christos Emmanouilides
The optimal management of locally advanced rectal cancer (LARC) often presents a therapeutic challenge. Balancing the benefits of treatment against toxicities and reducing the risk for local and distal recurrences are the mainstay of therapeutic approaches. Recently, several studies have compared a more aggressive approach of delivering several cycles of systemic chemotherapy to the established standard of combined chemoradiation. This approach is termed total neoadjuvant therapy and appears to be beneficial, at least for a subset of patients. The results of the main Phase III studies along with their variations in study design are hereby discussed with the goal of extracting useful clinical suggestions for treatment.
局部晚期直肠癌（LARC）的最佳治疗往往是一个治疗难题。平衡治疗效果与毒性，降低局部和远端复发的风险是治疗方法的主流。最近，有几项研究比较了一种更激进的方法，即提供几个周期的全身化疗，与既定标准的联合化放疗进行比较。这种方法被称为完全新辅助治疗，至少对一部分患者似乎是有益的。本文讨论了主要 III 期研究的结果及其不同的研究设计，旨在为临床治疗提供有用的建议。
{"title":"Total neoadjuvant therapy in rectal cancer: a review across studies","authors":"Ioannis Gavalas, M. Trichas, Christos Emmanouilides","doi":"10.2478/fco-2023-0014","DOIUrl":"https://doi.org/10.2478/fco-2023-0014","url":null,"abstract":"\u0000 The optimal management of locally advanced rectal cancer (LARC) often presents a therapeutic challenge. Balancing the benefits of treatment against toxicities and reducing the risk for local and distal recurrences are the mainstay of therapeutic approaches. Recently, several studies have compared a more aggressive approach of delivering several cycles of systemic chemotherapy to the established standard of combined chemoradiation. This approach is termed total neoadjuvant therapy and appears to be beneficial, at least for a subset of patients. The results of the main Phase III studies along with their variations in study design are hereby discussed with the goal of extracting useful clinical suggestions for treatment.","PeriodicalId":38592,"journal":{"name":"Forum of Clinical Oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140653550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
N. Shunyu, M. C. Balakrishnan, L. Dorjee, Ratan Medhi
Fungating growths are most distressing causing substantial psychological distress for patients and families. Malodor associated with fungating growth causes social isolation, yet malodor management remains suboptimal. Management of fungating cancer growth of oral cavity is unique and difficult. This paper discusses the management of malodor and infection associated with fungating wound including definitive treatment of fungating growth of an oral cavity cancer patient.
{"title":"Management of Fungating Oral Cancer: A Case Report","authors":"N. Shunyu, M. C. Balakrishnan, L. Dorjee, Ratan Medhi","doi":"10.2478/fco-2023-0015","DOIUrl":"https://doi.org/10.2478/fco-2023-0015","url":null,"abstract":"\u0000 Fungating growths are most distressing causing substantial psychological distress for patients and families. Malodor associated with fungating growth causes social isolation, yet malodor management remains suboptimal. Management of fungating cancer growth of oral cavity is unique and difficult. This paper discusses the management of malodor and infection associated with fungating wound including definitive treatment of fungating growth of an oral cavity cancer patient.","PeriodicalId":38592,"journal":{"name":"Forum of Clinical Oncology","volume":"31 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140656098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
I. Yudiana, Stacia Novia Marta, Ronald Sugianto, Anak Agung Wiradewi Lestari
Abstract Introduction The spread of penile cancer cells through lymphatic vessels provides the potential for using compounds involved in lymphangiogenesis, such as programmed death-ligand 1 (PD-L1), C-reactive protein (CRP), neutrophil/lymphocyte ratio (NLR), and Ki-67, in predicting the development of lymphatic metastases in penile cancer. Methods The systematic review was conducted based on the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) statement. A literature search was conducted using the medical literature database PubMed, Scopus, ScienceDirect, EMBASE, and EBSCOHost for studies published until February 7, 2023. Results Among 527 studies identified in the literature, 21 studies met the inclusion criteria and became eligible studies. PD-L1, CRP, and NLR are biomarkers which are proven to be significantly associated with an increased risk of high-grade tumor and lymphatic metastasis in penile cancer. Conclusion PD-L1, CRP, and NLR are biomarkers that might be used to assess the risk or likelihood of developing lymphatic metastases in penile cancer.
{"title":"Programmed Death-Ligand 1, C-reactive Protein, and Neutrophil/Lymphocyte Ratio as Lymphangiogenesis Markers of Metastasis in Penile Cancer – A Systematic Review","authors":"I. Yudiana, Stacia Novia Marta, Ronald Sugianto, Anak Agung Wiradewi Lestari","doi":"10.2478/fco-2023-0010","DOIUrl":"https://doi.org/10.2478/fco-2023-0010","url":null,"abstract":"Abstract Introduction The spread of penile cancer cells through lymphatic vessels provides the potential for using compounds involved in lymphangiogenesis, such as programmed death-ligand 1 (PD-L1), C-reactive protein (CRP), neutrophil/lymphocyte ratio (NLR), and Ki-67, in predicting the development of lymphatic metastases in penile cancer. Methods The systematic review was conducted based on the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) statement. A literature search was conducted using the medical literature database PubMed, Scopus, ScienceDirect, EMBASE, and EBSCOHost for studies published until February 7, 2023. Results Among 527 studies identified in the literature, 21 studies met the inclusion criteria and became eligible studies. PD-L1, CRP, and NLR are biomarkers which are proven to be significantly associated with an increased risk of high-grade tumor and lymphatic metastasis in penile cancer. Conclusion PD-L1, CRP, and NLR are biomarkers that might be used to assess the risk or likelihood of developing lymphatic metastases in penile cancer.","PeriodicalId":38592,"journal":{"name":"Forum of Clinical Oncology","volume":"53 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139125204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mansilla-Polo Miguel, Navarro-Mira Miguel Ángel, Botella-Estrada Rafael
Abstract Hydroxyurea is a cytotoxic drug that has been used for decades for the treatment of various entities, mostly hematologic, especially polycythemia vera. Its side effects are varied, including dermatological ones, ranging from skin xerosis to hyperpigmentation, lesions like dermatomyositis and shows even a relationship with premalignant processes (actinic keratosis) and non-melanoma cancer (squamous, basal cell, Merkel, and oral tumors). In this paper, we report a clinical case of a relatively frequent adverse effect of hydroxyurea, but of extraordinary localization and clinical presentation. The association of ulcers with taking hydroxyurea is well known. Most of the time, these appear in the lower limbs and in patients with chronic vascular pathology. However, in our patient, the location was both hands and was associated with dermatomyositis-like lesions, nail hyperpigmentation, and skin changes. The therapeutic response with withdrawal was spectacular. Knowledge of this condition is vitally important for the hematologist and dermatologist to ensure adequate care.
{"title":"Hydroxyurea ulcers of unusual location: a case report and review of literature","authors":"Mansilla-Polo Miguel, Navarro-Mira Miguel Ángel, Botella-Estrada Rafael","doi":"10.2478/fco-2023-0008","DOIUrl":"https://doi.org/10.2478/fco-2023-0008","url":null,"abstract":"Abstract Hydroxyurea is a cytotoxic drug that has been used for decades for the treatment of various entities, mostly hematologic, especially polycythemia vera. Its side effects are varied, including dermatological ones, ranging from skin xerosis to hyperpigmentation, lesions like dermatomyositis and shows even a relationship with premalignant processes (actinic keratosis) and non-melanoma cancer (squamous, basal cell, Merkel, and oral tumors). In this paper, we report a clinical case of a relatively frequent adverse effect of hydroxyurea, but of extraordinary localization and clinical presentation. The association of ulcers with taking hydroxyurea is well known. Most of the time, these appear in the lower limbs and in patients with chronic vascular pathology. However, in our patient, the location was both hands and was associated with dermatomyositis-like lesions, nail hyperpigmentation, and skin changes. The therapeutic response with withdrawal was spectacular. Knowledge of this condition is vitally important for the hematologist and dermatologist to ensure adequate care.","PeriodicalId":38592,"journal":{"name":"Forum of Clinical Oncology","volume":"52 31","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134993364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
B Pires, D Rothwell, I Guimarães, J Sousa, R Magalhães, T Serra, L Khouri, P Alves
Abstract Background The aim of this study was to compare the dosimetry of carotid arteries (CAs) using three radiation therapy (RT) techniques, three-dimensional conformal RT (3D-CRT), helical tomotherapy-intensity-modulated RT (HT-IMRT), and volumetric modulated arc therapy (VMAT), in patients with early-stage glottic cancer. Patients and Methods A retrospective analysis of 28 patients was performed, and the right and left CAs were delineated. Mean and maximum dose (Dmax) values were compared across the three treatment techniques. Results The results indicate that 3D-CRT plans had the highest mean and maximum doses to CAs, while VMAT plans had the lowest doses. Conclusions Our study demonstrates the feasibility of sparing CAs with newer RT modalities. Further clinical studies are needed to determine if these techniques can reduce carotid stenosis-related events.
{"title":"Comparison of Carotid Artery Dose in Early-Stage Glottic Cancer Treated with 3D-Conformal, Helical-IMRT and VMAT","authors":"B Pires, D Rothwell, I Guimarães, J Sousa, R Magalhães, T Serra, L Khouri, P Alves","doi":"10.2478/fco-2023-0009","DOIUrl":"https://doi.org/10.2478/fco-2023-0009","url":null,"abstract":"Abstract Background The aim of this study was to compare the dosimetry of carotid arteries (CAs) using three radiation therapy (RT) techniques, three-dimensional conformal RT (3D-CRT), helical tomotherapy-intensity-modulated RT (HT-IMRT), and volumetric modulated arc therapy (VMAT), in patients with early-stage glottic cancer. Patients and Methods A retrospective analysis of 28 patients was performed, and the right and left CAs were delineated. Mean and maximum dose (Dmax) values were compared across the three treatment techniques. Results The results indicate that 3D-CRT plans had the highest mean and maximum doses to CAs, while VMAT plans had the lowest doses. Conclusions Our study demonstrates the feasibility of sparing CAs with newer RT modalities. Further clinical studies are needed to determine if these techniques can reduce carotid stenosis-related events.","PeriodicalId":38592,"journal":{"name":"Forum of Clinical Oncology","volume":"52 29","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134993366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abstract Background Various experimental and epidemiological studies have been conducted to find the relationship between hematologic parameters like neutrophil-to-lymphocyte ratio (NLR) and prognosis in numerous solid malignancies. We conducted a similar study to assess the role of NLR as a prognostic marker in locally advanced head and neck cancer (HNC) treated with chemoradiation. Patients and methods A total of 60 patients of histopathologically proven, previously untreated, locally advanced HNC were included in this randomized, prospective study. They were stratified into five groups according to their NLR values (<2, 2–3, 3–4, 4–5, and >5). All 60 patients received the same concurrent chemoradiation with a radiation dose of 66 Gy in 33 fractions over 6.5 weeks with injection cisplatin 40 mg/m 2 weekly. Treatment-related toxicities were assessed weekly. Association of NLR was assessed with the outcomes as per the World Health Organization (WHO) response criteria. Informed consent was taken from all patients, and approval of institutional ethical committee was obtained. Results Complete response was observed to be maximum in patients with low NLR value of <2 (73% of patients). Higher percentage of treatment-related toxicities was also observed in groups with higher NLR values, that is, NLR 4–5 and >5. The association of NLR with treatment response was statistically significant on Pearson's chi-square test ( P = 0.019). Conclusion Our study was able to establish the relationship between NLR and treatment outcome in HNC patients treated by concurrent chemoradiation. Higher pretreatment NLR values were associated with poorer survival outcomes and increased treatment-induced toxicities.
{"title":"Assessment of Neutrophil-to-Lymphocyte Ratio as A Prognostic Marker in Locally Advanced Head and Neck Cancer Treated with Concomitant Chemoradiation","authors":"Elisha Servorip Targain, Ashok Chauhan, Diptajit Paul, Shailley Arora Sehgal, Abhishek Soni, Paramjeet Kaur","doi":"10.2478/fco-2023-0004","DOIUrl":"https://doi.org/10.2478/fco-2023-0004","url":null,"abstract":"Abstract Background Various experimental and epidemiological studies have been conducted to find the relationship between hematologic parameters like neutrophil-to-lymphocyte ratio (NLR) and prognosis in numerous solid malignancies. We conducted a similar study to assess the role of NLR as a prognostic marker in locally advanced head and neck cancer (HNC) treated with chemoradiation. Patients and methods A total of 60 patients of histopathologically proven, previously untreated, locally advanced HNC were included in this randomized, prospective study. They were stratified into five groups according to their NLR values (<2, 2–3, 3–4, 4–5, and >5). All 60 patients received the same concurrent chemoradiation with a radiation dose of 66 Gy in 33 fractions over 6.5 weeks with injection cisplatin 40 mg/m 2 weekly. Treatment-related toxicities were assessed weekly. Association of NLR was assessed with the outcomes as per the World Health Organization (WHO) response criteria. Informed consent was taken from all patients, and approval of institutional ethical committee was obtained. Results Complete response was observed to be maximum in patients with low NLR value of <2 (73% of patients). Higher percentage of treatment-related toxicities was also observed in groups with higher NLR values, that is, NLR 4–5 and >5. The association of NLR with treatment response was statistically significant on Pearson's chi-square test ( P = 0.019). Conclusion Our study was able to establish the relationship between NLR and treatment outcome in HNC patients treated by concurrent chemoradiation. Higher pretreatment NLR values were associated with poorer survival outcomes and increased treatment-induced toxicities.","PeriodicalId":38592,"journal":{"name":"Forum of Clinical Oncology","volume":"140 10","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136317001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：